II. Pathophysiology
- 
                          Antiphospholipid Antibodies bind cell membrane phospholipids (including vascular endothelium)- Antibody binding triggers inflammatory and prothrombotic changes
 
- Increases risk of recurrent thrombosis of any size vessel- Core features include arterial thrombosis, venous thrombosis and Recurrent Pregnancy Loss
 
- Highly associated with Systemic Lupus Erythematosus (SLE)- However, 60% of cases are not related to SLE
 
III. Risk Factors
- 
                          Rheumatologic Conditions- Systemic Lupus Erythematosus (40% of cases)
- Rheumatoid Arthritis (20% of RA patients are APLA positive)
 
- 
                          Genetic predisposition- Inherited Coagulopathy
- Various HLA markers
 
- Infections
- Medications
- Other factors- Recurrent Pregnancy Loss (20% are APLA positive)
 
IV. Associated Conditions
- Major clinical associations- Venous thrombosis
- Arterial thrombosis
- Recurrent Pregnancy Loss
- Thrombocytopenia
- Hemolytic Anemia
 
- Other clinical associations- Heart Valve abnormality (esp. mitral and aortic valves)
- Positive Coombs tests
- Livedo Reticularis
- Migraine Headaches
- Leg ulcers
- Myelopathy
- Chorea
- Pulmonary Hypertension
- Avascular necrosis
 
V. Labs
- 
                          Antiphospholipid Antibodies (APLA)- Background- Up to 10% of healthy patients are APLA positive at low titers- However persistently high titers occur in less than 1% of healthy patients
 
- APLA positive status is based on at least 1 of 3 markers positive- Positive tests should be confirmed with a second test at >=12 weeks after inital test
- Risk increases with the number of positive markers
 
 
- Up to 10% of healthy patients are APLA positive at low titers
- Anticardiolipin Antibody IgG and IgM (most sensitive test)- IgG > 20 GPL is positive (>40 GPL are associated with increased thrombotic events)
- IgM > 20 MPL units is positive
- Possibly IgA positive
 
- Anti-B2-Glycoprotein I Autoantibodies
- Lupus Anticoagulant (most specific test, but Test Sensitivity only 20%)
 
- Background
- Other lab findings- Partial Thromboplastin Time (PTT) prolonged
- Autoantibodies are present in 5% of healthy patients
- False PositiveVDRL (30-40%)
- Cytopenias
 
VI. Diagnosis: Revised Sapporo Criteria (2006)
- Diagnosis requires at least 1 clinical AND 1 lab criteria
- Clinical Criteria (at least one required)- Vascular Thrombosis (one or more events)- Arterial thrombosis OR
- Deep Vein Thrombosis (but NOT Superficial Thrombophlebitis) OR
- Small vessel thrombosis
 
- Recurrent Pregnancy Loss- Unexplained fetal death at >10 weeks OR
- Premature birth <34 weeks due to PIH or placental insufficiency OR
- Three of more serial Spontaneous Abortions <10 weeks without other cause (e.g. chromosomal, anatomic, hormonal)
 
 
- Vascular Thrombosis (one or more events)
- Lab Criteria- At least 1 of 3 Positive APLA (at high titers) by two tests spaced at least 12 weeks apart
 
VII. Prevention: Thrombotic Complications
- 
                          Anticoagulation
                          - 
                              Warfarin
                              - Moderate to high dose (INR >2 to 3) is protective
- Low dose (INR <1.9) does not prevent thrombosis
 
- 
                              Low Molecular Weight Heparin (LMWH)- May be used for APLA in pregnancy
 
- 
                              Aspirin
                              - Protects against pregnancy loss (in those with multiple losses)
- Does not protect against thrombosis
 
 
- 
                              Warfarin
                              
- 
                          Systemic Lupus Erythematosus and APLA positive- Hydroxychloroquine
- Consider Aspirin prophylaxis
 
- Avoid factors predisposing to thrombosis- Avoid Oral Contraceptive use
- Avoid Immobility
 
- Modify atherosclerotic risk factors
VIII. Complications
- See Associated Conditions above
- Catastrophic Anti-Phospholipid Antibody Syndrome (CAPS)
IX. Resources
- Not So Benign Antiphospholipid Antibody Syndrome (Hematologist)
